S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
S&P 500   5,010.67 (+0.87%)
DOW   38,250.43 (+0.70%)
QQQ   418.57 (+0.95%)
AAPL   166.25 (+0.76%)
MSFT   400.13 (+0.25%)
META   482.70 (+0.34%)
GOOGL   156.35 (+1.47%)
AMZN   176.89 (+1.29%)
TSLA   141.91 (-3.50%)
NVDA   790.43 (+3.73%)
AMD   148.10 (+1.00%)
NIO   4.01 (+5.53%)
BABA   70.83 (+2.55%)
T   16.29 (-1.33%)
F   12.83 (+5.68%)
MU   109.07 (+2.15%)
GE   150.23 (+1.47%)
CGC   7.81 (-1.51%)
DIS   112.34 (-0.24%)
AMC   3.41 (+7.91%)
PFE   26.35 (+1.35%)
PYPL   63.37 (+1.70%)
XOM   120.66 (+0.65%)
NASDAQ:OPT

Opthea (OPT) Stock Price, News & Analysis

$3.38
+0.08 (+2.42%)
(As of 03:35 PM ET)
Today's Range
$3.35
$3.40
50-Day Range
$2.88
$4.14
52-Week Range
$1.60
$4.42
Volume
7,607 shs
Average Volume
24,036 shs
Market Capitalization
$197.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Opthea MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
314.2% Upside
$14.00 Price Target
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.57) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.71 out of 5 stars

Medical Sector

585th out of 907 stocks

Biological Products, Except Diagnostic Industry

100th out of 154 stocks

OPT stock logo

About Opthea Stock (NASDAQ:OPT)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

OPT Stock Price History

OPT Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Opthea Appoints Sujal Shah to the Board of Directors
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Opthea Limited (OPT)
Opthea Limited ADRs Rise 31% on Raised Funding
Opthea to Present at the FLORetina 2023 Congress
See More Headlines
Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/22/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$16.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+324.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$110,000.00
Book Value
($0.10) per share

Miscellaneous

Free Float
56,526,000
Market Cap
$192.72 million
Optionable
Not Optionable
Beta
1.19
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Megan Baldwin M.A.I.C.D. (Age 49)
    MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director
    Comp: $599.73k
  • Ms. Judith J. Robertson B.A. (Age 63)
    M.B.A., Chief Commercial Officer
    Comp: $588.59k
  • Ms. Karen Adams CPA (Age 52)
    VP of Finance & Company Secretary
    Comp: $305.14k
  • Dr. Frederic Guerard M.S. (Age 51)
    Pharm.D., Chief Executive Officer
  • Mr. Peter F. Lang M.B.A. (Age 51)
    Chief Financial Officer
  • Ms. Sarika Gulhar Ph.D.
    Executive Director of Human Resources
  • Dr. Michael Gerometta Ph.D. (Age 59)
    Head of Chemistry, Manufacturing & Controls Development
    Comp: $127.66k
  • Mr. Bruno Gagnon BPHARM (Age 55)
    M.Sc., Senior Vice President of Global Clinical Operations
  • Dr. Kenneth Sall
    Chief Medical Officer
  • Dr. Fang Li Ph.D.
    Senior Vice President of Regulatory Affairs

OPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Opthea stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPT shares.
View OPT analyst ratings
or view top-rated stocks.

What is Opthea's stock price target for 2024?

2 brokerages have issued 12-month price targets for Opthea's stock. Their OPT share price targets range from $12.00 to $16.00. On average, they predict the company's share price to reach $14.00 in the next year. This suggests a possible upside of 314.2% from the stock's current price.
View analysts price targets for OPT
or view top-rated stocks among Wall Street analysts.

How have OPT shares performed in 2024?

Opthea's stock was trading at $2.95 at the beginning of the year. Since then, OPT stock has increased by 14.6% and is now trading at $3.38.
View the best growth stocks for 2024 here
.

What guidance has Opthea issued on next quarter's earnings?

Opthea updated its FY 2023 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $47.5 million-$47.5 million.

When did Opthea IPO?

Opthea (OPT) raised $161 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPT) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners